Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + olaparib
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Trastuzumab deruxtecan + olaparib is a combination therapy being investigated for the treatment of HER2-expressing solid tumors, including platinum-resistant high-grade serous ovarian carcinoma. Trastuzumab deruxtecan (Enhertu) is a HER2-directed antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload (deruxtecan) via a tetrapeptide-based cleavable linker. Olaparib (Lynparza) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. The rationale for this combination is to exploit the DNA-damaging effects of the topoisomerase I inhibitor payload delivered by the ADC and the DNA repair inhibition provided by the PARP inhibitor, potentially leading to synergistic antitumor activity in tumors with HER2 expression and DNA repair vulnerabilities.
- Brand names
- EnhertuLynparza
- Other names
- T-DXdtrastuzumab deruxtecanolaparib
02
Targets
TOP1 (DNA Topoisomerase I)PARP2 (Poly (adp-ribose) polymerase 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab deruxtecan + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + olaparib.